Sylvester Comprehensive Cancer Center

  • G040554 - Alderuccio, Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180681

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40554: A Phase I/II Trial Of Mosunetuzumab (BTCT4465A) As Consolidation Therapy In Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy And As Therapy In Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable To Tolerate Full-Dose Chemotherapy

    Eligibility Criteria - NCT03677154 *This information has been extracted from " www.clinicaltrials.gov"

  • RP6530+Romidepsin-1805 - Alderuccio, Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:
    RCemailImg Katherine Narvaez-Camacho
    RCphone 3052438063

    IRB: 20181179

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: RPS

    Enrolling Sites:

    Sylvester

    Title:

    RP6530+Romidepsin-1805: An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K d/┐ dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma

    Eligibility Criteria - NCT03770000 *This information has been extracted from " www.clinicaltrials.gov"

  • REGN5458 - Alderuccio, Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20190220

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: REGENERON PHARM INC

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

    Eligibility Criteria - NCT03761108 *This information has been extracted from " www.clinicaltrials.gov"

  • A041702 - Alencar, Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:
    RCemailImg Leanne Rodriguez
    RCphone 3052432383

    IRB: 20190399

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Gables
    Sylvester

    Title:

    A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

    Eligibility Criteria - NCT03737981 *This information has been extracted from " www.clinicaltrials.gov"

  • LOXO-BTK-18001 - Alencar, Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20190647

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Lymphoid Leukemia,Leukemia, Other

    Sponsor: LOXO ONCOLOGY

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Eligibility Criteria - NCT03740529 *This information has been extracted from " www.clinicaltrials.gov"

  • X15015 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20170602

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    X15015: A Phase I Trial of Pevonedistat in combination with VXLD chemotherapy for adolescent and young adults with relapsed/refractory Acute Lymphoblastic Leukemia

    Eligibility Criteria - NCT03349281 *This information has been extracted from " www.clinicaltrials.gov"

  • A051301 / BMT CTN 1201 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:
    RCemailImg Kirenia Correa
    RCphone 3052439590

    IRB: 20160676

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Sylvester

    Title:

    A RANDOMIZED DOUBLE-BLIND PHASE III STUDY OF IBRUTINIB DURING AND FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA OF THE ACTIVATED B-CELL SUBTYPE

    Eligibility Criteria - NCT02443077 *This information has been extracted from " www.clinicaltrials.gov"

  • EBV-CTL-301 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:
    RCemailImg Monica Sumoza
    RCphone 3052438266

    IRB: 20161024

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Atara

    Enrolling Sites:

    Sylvester

    Title:

    Multicenter, Open-Label, Phase 3 Trial of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Allogeneic Hematopoietic Cell Transplant (alloHCT) Patients with EBV-Associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) after Failure of Rituximab

    Eligibility Criteria - NCT03392142 *This information has been extracted from " www.clinicaltrials.gov"

  • EBV-CTL-302 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:
    RCemailImg Monica Sumoza
    RCphone 3052438266

    IRB: 20161025

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Atara

    Enrolling Sites:

    Sylvester

    Title:

    Multicenter, Open Label, Phase 3 Trial of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Solid Organ Transplant (SOT) Patients with EBV-Associated Post Transplant Lymphoproliferative Disease (EBV-PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

    Eligibility Criteria - NCT03394365 *This information has been extracted from " www.clinicaltrials.gov"

  • EA4151 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:
    RCemailImg Kirenia Correa
    RCphone 3052439590

    IRB: 20180272

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: ECOG

    Enrolling Sites:

    Sylvester

    Title:

    EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

    Eligibility Criteria - NCT03267433 *This information has been extracted from " www.clinicaltrials.gov"

  • 1630GCC - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:
    RCemailImg Monica Sumoza
    RCphone 3052438266

    IRB: 20180385

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: University of Maryland

    Enrolling Sites:

    Sylvester

    Title:

    1630GCC: A Pilot Study of Zydelig in Patients with B-cell Malignancies as Post-Autologous Transplant Remission Maintenance

    Eligibility Criteria - NCT03133221 *This information has been extracted from " www.clinicaltrials.gov"

  • ATA 129-EAP-901 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:
    RCemailImg Monica Sumoza
    RCphone 3052438266

    IRB: 20190076

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Atara

    Enrolling Sites:

    Sylvester

    Title:

    Expanded Access Protocol for Providing Tabelecleucel to Patients with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom there are No Appropriate Alternative Therapies

    Eligibility Criteria - NCT02822495 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190794 - Beitinjaneh Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20190794

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Lymphoid Leukemia,Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Other Hematopoietic

    Sponsor: PTI

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

    Eligibility Criteria - NCT03002519 *This information has been extracted from " www.clinicaltrials.gov"

  • M16-802 - Bradley, Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180388

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: ABBVIE

    Enrolling Sites:

    Sylvester

    Title:

    M16-802: A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

    Eligibility Criteria - NCT03625505 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190961 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20190961

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Other Hematopoietic

    Sponsor: FORTY SEVEN, INC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies

    Eligibility Criteria - NCT03248479 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple

    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • DCC-2618-01-001 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20170452

    SDG: Neurological Cancer
    Disease Site(s):

    Esophagus,Brain and Nervous System,Other Hematopoietic,Stomach,Small Intestine,Colon,Rectum,Other Digestive Organ

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    DCC-2618-01-001: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety,Tolerability, Efficacy, and Pharmacokinetics in Patients with AdvancedMalignancies

    Eligibility Criteria - NCT02571036 *This information has been extracted from " www.clinicaltrials.gov"

  • ADP-0011:008 - Hoffman, James

  • Investigator:
    James Hoffman
    RCname Email

    Coordinator:
    RCemailImg Micaela Martinez
    RCphone 3052439731

    IRB: 20170613

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    ADP-0011-008: Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE-1A Positive Relapsed and Refractory Multiple Myeloma

    Eligibility Criteria - NCT03168438 *This information has been extracted from " www.clinicaltrials.gov"

  • SGNBCMA-001 - Hoffman, James

  • Investigator:
    James Hoffman
    RCname Email

    Coordinator:
    RCemailImg Katherine Narvaez-Camacho
    RCphone 3052438063

    IRB: 20180619

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SEATTLE GENETICS

    Enrolling Sites:

    Sylvester

    Title:

    SGNBCMA-001: A Phase 1 Study of SEA-BCMA in Patients With Relapsed Or Refractory Multiple Myeloma

    Eligibility Criteria - NCT03582033 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190823 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20190823

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Ovary,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Lung

    Sponsor: Plexxikon

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies

    Eligibility Criteria - NCT03297424 *This information has been extracted from " www.clinicaltrials.gov"

  • BMT CTN Protocol 1506 - Jimenez, Antonio

  • Investigator:
    Antonio Jimenez
    RCname Email

    Coordinator:
    RCemailImg Monica Sumoza
    RCphone 3052438266

    IRB: 20170757

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Leukemia, Other

    Sponsor: ASTELLAS PHARMA US

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    BMT CTN PROTOCOL 1506: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

    Eligibility Criteria - NCT02997202 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160023 - Kobetz Erin

  • Investigator:
    Erin Kobetz
    RCname Email

    Coordinator:

    IRB: 20160023

    SDG: Population Sciences
    Disease Site(s):

    Cervix Uteri,Other Hematopoietic,Colon,Rectum,Liver

    Sponsor: NIMHD

    Enrolling Sites:

    Community Clinics
    Sylvester

    Title:

    Increasing Uptake of Evidence Based Screening Services through a CHW led multi modality intervention: South Florida Center for Reducing Health Disparities.

    Eligibility Criteria - NCT02970136 *This information has been extracted from " www.clinicaltrials.gov"

  • Zuma 9 - Lekakis, Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:
    RCemailImg Monica Sumoza
    RCphone 3052438266

    IRB: 20181106

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Kite

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects with Relapsed/Refractory Large B-Cell Lymphoma

    Eligibility Criteria - NCT03153462 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190640 - Lekakis Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:
    RCemailImg Kirenia Correa
    RCphone 3052439590

    IRB: 20190640

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Monocytic Leukemia

    Sponsor: Regimmune Corporation

    Enrolling Sites:

    Sylvester

    Title:

    An Open Label, Non-Randomized Multicenter Phase 2b, Study with a Safety Run-in to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft- Versus-Host Disease (aGvHD) Compared to Contemporary Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

    Eligibility Criteria - NCT04014790 *This information has been extracted from " www.clinicaltrials.gov"

  • Alexander - Lekakis, Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:
    RCemailImg Kirenia Correa
    RCphone 3052439590

    IRB: 20190669

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AUTOLUS

    Enrolling Sites:

    Sylvester

    Title:

    A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti PD1 Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Eligibility Criteria - NCT03287817 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160422 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Karin Suarez
    RCphone 3052436995

    IRB: 20160422

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Memorial Sloan-Kettering Cancer Center

    Enrolling Sites:

    Gables
    Sylvester

    Title:

    DNA SEQUENCING-BASED MONITORING OF MINIMAL RESIDUAL DISEASE TO PREDICT CLINICAL RELAPSE IN AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS

    Eligibility Criteria - NCT02633111 *This information has been extracted from " www.clinicaltrials.gov"

  • LYMRIT-37-05 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20160851

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Lymphoid Leukemia

    Sponsor: Nordic

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 Dose finding study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin«) in patients with relapsed, diffuse large B-cell lymphoma, not eligible for autologous stem cell transplant

    Eligibility Criteria - NCT02658968 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170664 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Karin Suarez
    RCphone 3052436995

    IRB: 20170664

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Incyte Corporation

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    INCB 50465-204: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

    Eligibility Criteria - NCT03144674 *This information has been extracted from " www.clinicaltrials.gov"

  • GSK3326595 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180040

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Breast,Brain and Nervous System,Non-Hodgkin Lymphoma

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    GSK204653: A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

    Eligibility Criteria - NCT02783300 *This information has been extracted from " www.clinicaltrials.gov"

  • ACE-LY-003 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180457

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Acerta

    Enrolling Sites:

    Sylvester

    Title:

    ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT02180711 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180458 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Karin Suarez
    RCphone 3052436995

    IRB: 20180458

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: NCI

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    ILyAD (Indolent Lymphoma And Vitamin D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab Therapy

    Eligibility Criteria - NCT03078855 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40516 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180637

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40516:An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, and Efficacy Of Mosunetuzumab (BTCT4465A) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma Lymphoma

    Eligibility Criteria - NCT03671018 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40515 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180638

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40515: A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating The Safety, Tolerability, Pharmacokinetics, And Efficacy OfMosunetuzumab (BTCT4465) In Combination With CHOP or CHP-PolatuzumabVedotin In Patients With B-Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT03677141 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • TTX-030-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20181017

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Colon,Pancreas

    Sponsor: TTH

    Enrolling Sites:

    Sylvester

    Title:

    TTX-030-001 : Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy inPatients with Lymphoma or Solid Tumor Malignancies

    Eligibility Criteria - NCT03884556 *This information has been extracted from " www.clinicaltrials.gov"

  • 040-00 - Morris, Michele

  • Investigator:
    Michele Morris
    RCname Email

    Coordinator:
    RCemailImg Kirenia Correa
    RCphone 3052439590

    IRB: 20190280

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Other Hematopoietic,Monocytic Leukemia

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Sylvester

    Title:

    040-01: A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post-transplant in cytomegalovirus (CMV) seropositive recipients (R+) of an allogenic hematopoietic stem cell transplant (HSCT)

    Eligibility Criteria - NCT03930615 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170880 - Pereira Denise

  • Investigator:
    Denise Pereira
    RCname Email

    Coordinator:
    RCemailImg Kirenia Correa
    RCphone 3052439590

    IRB: 20170880

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: BIOLINE RX, LTD

    Enrolling Sites:

    Sylvester

    Title:

    BL-8040.SCM.301: A Phase III, Randomized, Double-Blinded Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS with Multiple Myeloma-The GENESIS Study

    Eligibility Criteria - NCT03246529 *This information has been extracted from " www.clinicaltrials.gov"

  • C-500-01 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160238

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Brain and Nervous System,Leukemia, Other,Bones and Joints,Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-500-01

    Eligibility Criteria - NCT02694822 *This information has been extracted from " www.clinicaltrials.gov"

  • 20150567 - Ramos Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:
    RCemailImg Sarah Lam
    RCphone 3052437586

    IRB: 20150567

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Leukemia, Other

    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase II Trial of Belinostat as Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma

    Eligibility Criteria - NCT02737046 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:
    RCemailImg Sarah Lam
    RCphone 3052437586

    IRB: 20160656

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Other Hematopoietic,Anus,Lung

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-101 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:
    RCemailImg Leanne Rodriguez
    RCphone 3052432383

    IRB: 20180056

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    AMC-101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas A Trial of the AIDS Malignancy Consortium (AMC)

    Eligibility Criteria - NCT03220022 *This information has been extracted from " www.clinicaltrials.gov"

  • Zuma 5 - Rosenblatt, Joseph

  • Investigator:
    Joseph Rosenblatt
    RCname Email

    Coordinator:
    RCemailImg Monica Sumoza
    RCphone 3052438266

    IRB: 20170361

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Kite

    Enrolling Sites:

    Sylvester

    Title:

    KTE-C19-105: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

    Eligibility Criteria - NCT03105336 *This information has been extracted from " www.clinicaltrials.gov"

  • CITN-13 - Schatz, Jonathan

  • Investigator:
    Jonathan Schatz
    RCname Email

    Coordinator:
    RCemailImg Karin Suarez
    RCphone 3052436995

    IRB: 20180920

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Mycosis Fungoides

    Sponsor: Cancer Immunotherapy Trials Network

    Enrolling Sites:

    Sylvester

    Title:

    CITN-13 :A Phase II Trial Of MK-3475 (Pembrolizumab) And Interferon Gamma 1-B Combination Immunotherapy In Patients With Previously Treated Mycosis Fungoides And SÚzary Syndrome (Treatment Group 1) And In Patients With Advanced Synovial Sarcoma (Treatment Group 2)

    Eligibility Criteria - NCT03063632 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • CCTL019B20031 - Wang, Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20190006

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Lymphoid Leukemia

    Sponsor: NOVARTIS

    Enrolling Sites:

    Sylvester

    Title:

    CCTL019B2003I: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

    Eligibility Criteria - NCT03601442 *This information has been extracted from " www.clinicaltrials.gov"

  • BMT CTN 1703/1801 - Wang, Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20190338

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Other Hematopoietic,Mycosis Fungoides

    Sponsor: BMT CTN

    Enrolling Sites:

    Sylvester

    Title:

    BMT CTN 1703/1801: A Randomized, Multicenter Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative / Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

    Eligibility Criteria - NCT03959241 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190836 - Wang Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20190836

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Multiple Myeloma,Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Other Hematopoietic

    Sponsor: EQUILLIUM INC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease

    Eligibility Criteria - NCT03763318 *This information has been extracted from " www.clinicaltrials.gov"

  • FORMA 2102-HEM-101 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20160327

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified

    Sponsor: FORMA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

    Eligibility Criteria - NCT02719574 *This information has been extracted from " www.clinicaltrials.gov"

  • VICC HEM 16146 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Leanne Rodriguez
    RCphone 3052432383

    IRB: 20171090

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Vanderbilt

    Enrolling Sites:

    Sylvester

    Title:

    VICC HEM16146: A phase II trial of Pevonedistat and Azacitidine in MDS or MDS/MPN patients who fail primary therapy with DNA methyl transferase inhibitors

    Eligibility Criteria - NCT03238248 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180054 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180054

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination with Low Dose Cytarabine (LDAC) in Adult Patients with Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS)

    Eligibility Criteria - NCT03459859 *This information has been extracted from " www.clinicaltrials.gov"

  • M16-186 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180197

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: ABBVIE

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Eligibility Criteria - NCT03441555 *This information has been extracted from " www.clinicaltrials.gov"

  • IMG-7289 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20180198

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other

    Sponsor: Imago

    Enrolling Sites:

    Sylvester

    Title:

    A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis.

    Eligibility Criteria - NCT03136185 *This information has been extracted from " www.clinicaltrials.gov"

  • 208809 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone 3052438990

    IRB: 20180677

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    208809: A Phase I/II Study To Investigate The Safety And Clinical Activity Of GSK3326595 And Other Agents In Subjects With Myelodysplastic Syndrome And Acute Myeloid Leukaemia.

    Eligibility Criteria - NCT03614728 *This information has been extracted from " www.clinicaltrials.gov"

  • 5001 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Charles Chen
    RCphone 3052431783

    IRB: 20180739

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Myeloid and Monocytic Leukemia,Leukemia, Other

    Sponsor: Aptevo Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    5001:Phase 1/1b Open-Label, Dose-Escalation Study of APVO436 in Patients with Relapsed or Refractory AML or High-Grade MDS

    Eligibility Criteria - NCT03647800 *This information has been extracted from " www.clinicaltrials.gov"

  • KTE-C19-104 - Ziga, Edward

  • Investigator:
    Edward Ziga
    RCname Email

    Coordinator:

    IRB: 20160129

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: Kite

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)

    Eligibility Criteria - NCT02625480 *This information has been extracted from " www.clinicaltrials.gov"